Fig. 4: Binding of CD23:IgE complexes by ligelizumab or omalizumab. | Nature Communications

Fig. 4: Binding of CD23:IgE complexes by ligelizumab or omalizumab.

From: The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab

Fig. 4

a Association and dissociation of IgE to immobilized human recombinant CD23 by SPR. Each color refers to an individual measurement cycle. Curves were fitted (black dashed lines) using a two-state reaction binding model. b Binding of ligelizumab and omalizumab IgG to CD23 pre-complexed human recombinant IgE was measured by SPR. c Binding of polyclonal anti-IgG to CD23:IgE:anti-IgE complexes was assessed by SPR. d Flow cytometric quantification of IgE (d) and IgG (e) surface levels on CD23-expressing RPMI8866 cells after treatment with ligelizumab, omalizumab or isotype IgG with or without blocking of CD23 prior to IgE sensitization (data for technical duplicates are displayed as mean ± SEM). Representative flow cytometry plots (f) and quantification of IgG-positive RPMI8866 cell frequencies (g) after treatment with ligelizumab or omalizumab with or without blocking of CD23 prior to IgE sensitization (data for technical duplicates are displayed as mean ± SEM). Representative image stream flow cytometry pictures for CD23-, IgE- and IgG staining (h) and co-localization analysis for IgE- and IgG staining (i) of IgE-sensitized RPMI8866 cells after treatment with ligelizumab, omalizumab or isotype IgG. Source data are provided as Source Data file.

Back to article page